{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:54:33Z","timestamp":1789786473894,"version":"4.0.1"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Congenital adrenal hyperplasia (CAH), most commonly caused by 21-hydroxylase deficiency, remains associated with substantial morbidity despite life-saving glucocorticoid replacement. This review is timely because several novel therapies have recently emerged with the potential to improve disease control while reducing glucocorticoid burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Recent advances in CAH management include modified-release hydrocortisone, which better mimics physiological cortisol secretion and may improve androgen control with lower glucocorticoid exposure. Steroid-reducing agents have advanced rapidly, particularly the corticotropin-releasing factor type 1 receptor antagonist crinecerfont and the melanocortin 2 receptor (MC2R) antagonist atumelnant, both of which show promise in lowering adrenocorticotropic hormone (ACTH)-driven androgen excess and facilitating glucocorticoid dose reduction. Additional emerging approaches include insurmountable MC2R antagonists and the anti-ACTH monoclonal antibody Lu AG13909. Gene therapy and genome editing strategies are also progressing, although important biological and technical barriers remain, particularly for durable adrenal targeting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The therapeutic landscape for CAH is evolving rapidly beyond conventional steroid replacement. These innovations may improve biochemical control and long-term outcomes, but challenges remain regarding adrenal crisis risk, long-term safety, durability, cost, and global equity of access.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000001583","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:00:22Z","timestamp":1780509622000},"page":"434-439","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Advances in pharmacological treatment for congenital adrenal hyperplasia"],"prefix":"10.1097","volume":"38","author":[{"given":"Lara E.","family":"Graves","sequence":"first","affiliation":[{"name":"Institute of Endocrinology and Diabetes, the Children's Hospital at Westmead"},{"name":"Gene Therapy Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney and Sydney Children's Hospitals Network"},{"name":"Discipline of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Falhammar","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet"},{"name":"Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management","volume":"43","author":"Claahsen-van der Grinten","year":"2022","journal-title":"Endocr Rev"},{"key":"R2-20260702","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society Clinical Practice Guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S2213-8587(13)70007-X","article-title":"One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study","volume":"1","author":"Gidlof","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"bvaf018","DOI":"10.1210\/jendso\/bvaf018","article-title":"Genetics in congenital adrenal hyperplasia due to 21-hydroxylase deficiency and clinical implications","volume":"9","author":"Concolino","year":"2025","journal-title":"J Endocr Soc"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jcem-11-1-1","article-title":"Treatment of congenital adrenal hyperplasia with cortisone","volume":"11","author":"Wilkins","year":"1951","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1172\/JCI102438","article-title":"The effects of adrenocorticotropic hormone and cortisone in the adrenogenital syndrome associated with congenital adrenal hyperplasia: an attempt to explain and correct its disordered hormonal pattern","volume":"30","author":"Bartter","year":"1951","journal-title":"J Clin Invest"},{"key":"R7-20260702","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3803\/EnM.2022.1528","article-title":"Long-term outcomes of congenital adrenal hyperplasia","volume":"37","author":"Nordenstrom","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R8-20260702","first-page":"268","article-title":"Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"67","author":"Bachelot","year":"2007","journal-title":"Horm Res"},{"key":"R9-20260702","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/endrev\/bnae026","article-title":"Cardiometabolic aspects of congenital adrenal hyperplasia","volume":"46","author":"Krysiak","year":"2025","journal-title":"Endocr Rev"},{"key":"R10-20260702","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1210\/clinem\/dgab712","article-title":"Increased prevalence of fractures in congenital adrenal hyperplasia: a Swedish Population-based National Cohort Study","volume":"107","author":"Falhammar","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20260702","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3389\/fendo.2020.00493","article-title":"Bone mineral density in adults with congenital adrenal hyperplasia: a systematic review and meta-analysis","volume":"11","author":"Rangaswamaiah","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R12-20260702","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3803\/EnM.2021.1328","article-title":"Epidemiology and long-term adverse outcomes in korean patients with congenital adrenal hyperplasia: a nationwide study","volume":"37","author":"Kim","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R13-20260702","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/EJE-17-0895","article-title":"Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia","volume":"178","author":"Jenkins-Jones","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"R14-20260702","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1210\/jc.2014-3191","article-title":"High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study","volume":"100","author":"Hahner","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20260702","doi-asserted-by":"crossref","first-page":"E2715","DOI":"10.1210\/jc.2014-2957","article-title":"Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"99","author":"Falhammar","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-20260702","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-20260702","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/cen.12316","article-title":"An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure","volume":"80","author":"Whitaker","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R18-20260702","doi-asserted-by":"crossref","first-page":"e2063","DOI":"10.1210\/clinem\/dgab051","article-title":"Modified-release hydrocortisone in congenital adrenal hyperplasia","volume":"106","author":"Merke","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-20260702","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/ejendo\/lvaf130","article-title":"Long-term outcomes in patients with congenital adrenal hyperplasia treated with hydrocortisone modified-release hard capsules","volume":"193","author":"Arlt","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"R20-20260702","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S2213-8587(17)30398-4","article-title":"Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial","volume":"6","author":"Isidori","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R21-20260702","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1530\/EJE-14-1114","article-title":"Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency","volume":"172","author":"Quinkler","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"R22-20260702","doi-asserted-by":"crossref","first-page":"103714","DOI":"10.1016\/j.eclinm.2025.103714","article-title":"Effects of modified release hydrocortisone on restoration of early morning cortisol, quality of life, and fatigue in adrenal insufficiency (The CHAMPAIN study): a randomised, double-blind, double-dummy, cross-over study comparing Chronocort and Plenadren","volume":"91","author":"Prete","year":"2026","journal-title":"EClinicalMedicine"},{"key":"R23-20260702","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1210\/jc.2009-0630","article-title":"Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion","volume":"94","author":"Bryan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-20260702","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/EJE-07-0052","article-title":"Continuous subcutaneous hydrocortisone infusion in Addison's disease","volume":"157","author":"Lovas","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"R25-20260702","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1210\/jc.2016-1916","article-title":"A phase 2 study of continuous subcutaneous hydrocortisone infusion in adults with congenital adrenal hyperplasia","volume":"101","author":"Nella","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-20260702","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/cen.13813","article-title":"Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia","volume":"89","author":"Mallappa","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R27-20260702","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-21-0794","article-title":"Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia","volume":"186","author":"Prete","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"R28-20260702","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41574-025-01089-w","article-title":"Recent advances in treatments for congenital adrenal hyperplasia","volume":"21","author":"Falhammar","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"R29-20260702","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2404656","article-title":"Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia","volume":"391","author":"Auchus","year":"2024","journal-title":"N Engl J Med"},{"key":"R30-20260702","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2404655","article-title":"Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia","volume":"391","author":"Sarafoglou","year":"2024","journal-title":"N Engl J Med"},{"key":"R31-20260702","doi-asserted-by":"crossref","first-page":"1693063","DOI":"10.3389\/fendo.2025.1693063","article-title":"What is the need for adrenalectomy in patients with congenital adrenal hyperplasia in the era of CRF1\/ACTH inhibitors?","volume":"16","author":"Fedorova","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R32-20260702","doi-asserted-by":"crossref","first-page":"e4666","DOI":"10.1210\/clinem\/dgab438","article-title":"Tildacerfont in adults with classic congenital adrenal hyperplasia: results from two phase 2 studies","volume":"106","author":"Sarafoglou","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-20260702","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1021\/acsmedchemlett.3c00514","article-title":"Discovery of CRN04894: a novel potent selective MC2R antagonist","volume":"15","author":"Kim","year":"2024","journal-title":"ACS Med Chem Lett"},{"issue":"(Suppl 1)","key":"R36-20260702","article-title":"12537 Once daily oral atumelnant (CRN04894) induces rapid and profound reductions of androstenedione and 17-hydroxyprogesterone in participants with classical congenital adrenal hyperplasia: initial results from a 12-week, phase 2, open-label study","volume":"8","author":"Auchus","year":"2024","journal-title":"J Endocr Soc"},{"issue":"(Suppl 1)","key":"R37-20260702","article-title":"SAT-452 reductions in adrenal volume in patients with congenital adrenal hyperplasia receiving once-daily oral atumelnant (CRN04894): interim results from a 12-week, phase 2, open-label study","volume":"9","author":"Bachega","year":"2025","journal-title":"J Endocr Soc"},{"issue":"(Suppl 1)","key":"R38-20260702","article-title":"SUN-432 optimizing binding kinetics to develop insurmountable MC2 receptor antagonists for the treatment of congenital adrenal hyperplasia","volume":"9","author":"Sanz","year":"2025","journal-title":"J Endocr Soc"},{"issue":"(Suppl 1)","key":"R39-20260702","article-title":"12484 Safety and pharmacokinetics of anti-ACTH antibody Lu AG13909 in patients with classic congenital adrenal hyperplasia: phase 1 open-label, multiple-ascending-dose trial protocol","volume":"8","author":"Srirangalingam","year":"2024","journal-title":"J Endocr Soc"},{"issue":"(Suppl 1)","key":"R40-20260702","article-title":"MON-468 a novel anti-ACTH antibody Lu AG13909 in clinical development for treatment of classic congenital adrenal hyperplasia: a phase 1 open-label, multiple-ascending-dose study","volume":"9","author":"Johannsson","year":"2025","journal-title":"J Endocr Soc"},{"key":"R41-20260702","doi-asserted-by":"crossref","first-page":"e2198","DOI":"10.1210\/clinem\/dgae771","article-title":"Anastrozole improves height outcomes in growing children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Al-Rayess","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"R42-20260702","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1210\/clinem\/dgac751","article-title":"Future directions for adrenal insufficiency: cellular transplantation and genetic therapies","volume":"108","author":"Graves","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"R43-20260702","doi-asserted-by":"crossref","first-page":"101","DOI":"10.37349\/eemd.2024.00011","article-title":"Genome editing in the adrenal gland: a novel strategy for treating congenital adrenal hyperplasia","volume":"1","author":"van Dijk","year":"2024","journal-title":"Explor Endocr Metab Dis"},{"key":"R44-20260702","doi-asserted-by":"crossref","first-page":"1719376","DOI":"10.3389\/fendo.2025.1719376","article-title":"Exploration of the potential of genomic editing in the treatment of congenital adrenal hyperplasia","volume":"16","author":"Graves","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R45-20260702","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/gt.2017.10","article-title":"An AAVrh10-CAG-CYP21-HA vector allows persistent correction of 21-hydroxylase deficiency in a Cyp21(-\/-) mouse model","volume":"24","author":"Perdomini","year":"2017","journal-title":"Gene Ther"},{"key":"R46-20260702","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/hum.2017.203","article-title":"Biology of the adrenal gland cortex obviates effective use of adeno-associated virus vectors to treat hereditary adrenal disorders","volume":"29","author":"Markmann","year":"2018","journal-title":"Hum Gene Ther"},{"key":"R47-20260702","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.stem.2019.04.012","article-title":"The adult adrenal cortex undergoes rapid tissue renewal in a sex-specific manner","volume":"25","author":"Grabek","year":"2019","journal-title":"Cell Stem Cell"},{"key":"R48-20260702","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/mt.2008.72","article-title":"Gene delivery to the juvenile mouse liver using AAV2\/8 vectors","volume":"16","author":"Cunningham","year":"2008","journal-title":"Mol Ther"},{"key":"R49-20260702","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"R50-20260702","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Preexisting antiadeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum Gene Ther Methods"},{"key":"R51-20260702","doi-asserted-by":"crossref","first-page":"101232","DOI":"10.1016\/j.omtm.2024.101232","article-title":"AAV-delivered hepato-adrenal cooperativity in steroidogenesis: implications for gene therapy for congenital adrenal hyperplasia","volume":"32","author":"Graves","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R52-20260702","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.ymthe.2025.11.011","article-title":"Targeted editing of the 21-hydroxylase locus confers durable therapeutic effect in a murine model of congenital adrenal hyperplasia","volume":"34","author":"Graves","year":"2026","journal-title":"Mol Ther"},{"key":"R53-20260702","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ng1380","article-title":"Adeno-associated virus vectors integrate at chromosome breakage sites","volume":"36","author":"Miller","year":"2004","journal-title":"Nat Genet"},{"key":"R54-20260702","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat Biotechnol"},{"key":"R55-20260702","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-019-09006-2","article-title":"CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations","volume":"10","author":"Cullot","year":"2019","journal-title":"Nat Commun"},{"key":"R56-20260702","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat Genet"},{"key":"R57-20260702","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41587-024-02171-w","article-title":"Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors","volume":"43","author":"Suchy","year":"2025","journal-title":"Nat Biotechnol"},{"key":"R58-20260702","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat Commun"},{"key":"R59-20260702","doi-asserted-by":"crossref","first-page":"1582097","DOI":"10.3389\/fgeed.2025.1582097","article-title":"Long read sequencing reveals transgene concatemerization and vector sequences integration following AAV-driven electroporation of CRISPR RNP complexes in mouse zygotes","volume":"7","author":"Luqman","year":"2025","journal-title":"Front Genome Ed"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:00:52Z","timestamp":1782979252000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001583","relation":{},"ISSN":["1531-698X"],"issn-type":[{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}